Nov 2 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO) raised its full-year earnings outlook on strong sales of diabetes treatment Ozempic, also reporting a better-than-expected profit. Nine-month operating profit rose 28% to 57.7 billion Danish crowns ($7.66 billion), above the 56.8 billion forecast by analysts, according to Refinitiv data. It reiterated that it expects to make all doses of weight-loss drug Wegovy, a future growth driver, available in the United States towards the end of 2022, as it seeks to overcome production problems. "The growth is driven by increasing demand for GLP-1-based diabetes treatments, especially Ozempic," CEO Lars Fruergaard Jorgensen said. Novo faces keen competition from Eli Lilly, whose monthly injection Mounjaro won U.S. approval for type 2 diabetes in May and it is under fast-track review as a potential weight-loss drug.

---